Manning & Napier Advisors LLC Has $13.65 Million Holdings in Gilead Sciences, Inc. $GILD

Manning & Napier Advisors LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 46.9% in the 3rd quarter, Holdings Channel reports. The firm owned 121,237 shares of the biopharmaceutical company’s stock after selling 107,065 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Gilead Sciences were worth $13,654,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. GoalVest Advisory LLC boosted its holdings in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $27,000. Putney Financial Group LLC increased its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the period. Finally, Howard Hughes Medical Institute bought a new position in Gilead Sciences during the second quarter worth $30,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.7%

GILD opened at $121.76 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $89.83 and a fifty-two week high of $128.70. The firm has a market capitalization of $151.07 billion, a PE ratio of 18.88, a P/E/G ratio of 0.64 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company’s 50-day moving average is $123.25 and its 200 day moving average is $117.85.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on GILD shares. Royal Bank Of Canada increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. HSBC raised their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. UBS Group initiated coverage on Gilead Sciences in a research note on Wednesday, January 7th. They issued a “buy” rating and a $145.00 price target on the stock. Citigroup increased their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.16.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 130,757 shares of company stock worth $16,205,752. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.